Both parties publicly confirmed the AstraZeneca collaboration. A 2026 financing announcement states that proceeds will advance the pipeline into clinical development; specific human oral PK data were not disclosed.
Mainland ChinaFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
32 matching companiesShowing 1–24 / 32
The company website confirms the Macoral® / Simgut® platform and collaboration with BrightGene. The pipeline image reviewed is historical; current clinical stages require confirmation.
Mainland ChinaFull profile →
Uses AI to design macrocycles de novo. The website lists oral / cell-permeable approaches and an α4β7 IBD program; website percentages are not converted into clinical-stage assignments.
United StatesFull profile →
Uses AI, physics-based simulation, peptide chemistry, and oral formulation development for oral immunology and cardiometabolic peptides; operates in Shanghai and Pennsylvania.
Mainland China / United StatesFull profile →
HS-20118 / AVR-001 is an oral IL-23R cyclic peptide with disclosed Phase 1 human data. Rights outside Greater China were licensed to Avere.
Mainland ChinaFull profile →
The website explicitly identifies an ORALINK oral α4β7 cyclic peptide co-development program with D&D at lead optimization, recorded separately from radiopharmaceutical / conjugate programs.
South KoreaFull profile →
On 2026-10-22, the company announced a proposed acquisition of PepStar's HCXT-2001 oral macrocyclic peptide program. Its Q3 announcement confirms Phase 1; closing conditions remain outstanding.
United StatesFull profile →
Uses AI to design oral IL-17A/F inhibitors. The company describes fully synthetic, compact cyclic peptidomimetics containing nonnatural amino acids.
IsraelFull profile →
Collaborates with Biogen to discover and optimize oral macrocyclic peptides for immune diseases. Named targets, candidates, and human results have not been disclosed.
CanadaFull profile →
Industry partner for Dayra's oral macrocyclic peptide collaboration, responsible for subsequent development and potential commercialization. Its role is recorded separately from Dayra's using a shared program identifier.
United StatesFull profile →
An investor record describes program 629 as an oral IL-23 cyclic peptide with PK suggesting once-weekly potential. Human results and the latest stage were not confirmed in this review.
Mainland ChinaFull profile →
An October 2026 research collaboration and exclusive option agreement with Generian advances an oral macrocyclic peptide FcRn antagonist. This research-stage program is separate from Processa’s Phase 2 small-molecule BTK inhibitor VT-7208.
United StatesFull profile →
A company emerging from the UPMC/University of Pittsburgh ecosystem, Generian entered an October 2026 research collaboration and exclusive option arrangement with Processa for an oral macrocyclic peptide FcRn antagonist.
United StatesFull profile →
The website reports Novartis licensing of the VAV1 molecular glue MRT-6160 and Phase 2 studies. The NEK7 molecular glue MRT-8102 completed Phase 1 GFORCE-1; MRT-2359 is in clinical combination development.
United StatesFull profile →
Develops mRNA cell therapies, with a lead program based on ex vivo mRNA CAR-T. It also collaborates with WestGene on in vivo tLNP delivery; these approaches should be evaluated separately.
United StatesFull profile →
A clinical-stage self-replicating RNA technology developer spanning infectious diseases, immunology, and other therapeutic areas.
United StatesFull profile →
Aanastra discloses PEP-CAR, an anti-CD19 in vivo CAR-T strategy combining engineered RNA and targeting peptides for cancer and autoimmune disease. The public website does not establish a registered clinical program or validated patient outcomes.
AERA-109 is a targeted-LNP in vivo CAR-T candidate for B-cell-mediated autoimmune diseases, supported by mouse and nonhuman-primate studies. The pipeline projects clinical entry in the second half of 2026; a projected date is not proof that dosing has begun.
United StatesFull profile →
AlphaNa identifies AFN50 as an mRNA-based in vivo CAR-T program for autoimmune disease currently evaluated in IITs. The disclosed program is classified as investigator-initiated research; unrelated RNA programs and inconsistent codes elsewhere on the website are not used to infer additional CAR-T assets.
Mainland ChinaFull profile →
Develops circular RNA (oRNA) and LNP delivery. Its current LinkedIn page identifies it as a wholly owned Eli Lilly subsidiary, so it should not be treated as an independent private platform company.
United StatesFull profile →
An RNA and in vivo immune reprogramming platform developer; the website identifies it as a Bristol Myers Squibb company.
United StatesFull profile →
STX-001 is an intratumoral self-replicating mRNA treatment encoding IL-12. The company discloses a Phase 1 study and a broader programmable RNA platform.
United StatesFull profile →
Founded in 2019, the company develops mRNA, self-replicating RNA, and delivery platforms. In 2026 it reported early JCXH-213 results in two patients with ITP; these findings should be distinguished from formal registered-trial phases and independent validation.
Mainland ChinaFull profile →
Starna’s pipeline includes STR-P004 and STR-P005 in vivo CAR-T programs for autoimmune disease. An ASCO abstract describes CD19 CAR mRNA in CD8-targeted LNPs and exploratory patient dosing for STR-P004. These early findings do not establish efficacy or the stage of STR-P005.
Mainland ChinaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.